logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

JST GROUP (06687) repurchased 459,200 shares on November 11 for HK$5.2503 million.

date
21:30 11/11/2026
avatar
GMT Eight
JST GROUP (06687) announced that on November 11, 2026, it repurchased 459,200 shares for HK$5.2503 million.
JST GROUP (06687) announced that on November 11, 2026, it repurchased 459,200 shares for HK$5.2503 million.
Related Articles
US Stock Market Move | Nasdaq futures surge 1.91%; most star tech stocks rise in premarket trading.
HK Stock
One Micro Technology (02065) Hong Kong public offering received 13.95 times subscription; global offering raised net proceeds of approximately HK$655.9 million
HK Stock
Monotherapy for glucose lowering surpasses tirzepatide, and in head-to-head combination therapy it is superior to semaglutide: Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) BGM0504 competes for the global glucose-lowering benchmark.
US Stock Market Move | Nasdaq futures surge 1.91%; most star tech stocks rise in premarket trading.
One Micro Technology (02065) Hong Kong public offering received 13.95 times subscription; global offering raised net proceeds of approximately HK$655.9 million
HK Stock
Monotherapy for glucose lowering surpasses tirzepatide, and in head-to-head combination therapy it is superior to semaglutide: Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) BGM0504 competes for the global glucose-lowering benchmark.
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.